Novo Integrated Sciences, Inc. Overview
Pro stress-test →Novo Integrated Sciences (NASDAQ: NVOS) owns Canadian and U.S. subsidiaries which deliver multidisciplinary primary health care related services and products through the integration of medical technology, advanced therapeutics and rehabilitative science. The company pioneers a holistic, decentralized approach to healthcare, leveraging medical technology, advanced therapeutics, and rehabilitative science.
Strategic Profile
Pro stress-test →Currently, the Company's revenue is generated solely through its wholly owned Canadian subsidiary, Novo Healthnet Limited (NHL). The company provides medical technology platforms, such as Novo Connect, telemedicine/telehealth, and remote patient monitoring; and develops and distributes personalized health and wellness product solutions. The company is pursuing aggressive capital expansion through a $78 million Standby Letter of Credit monetization (anticipated completion August 2025) to fund acquisitions and operations.
Competitive Landscape
Pro stress-test →Novo competes in the fragmented primary care and integrated healthcare services market against regional physiotherapy chains, telehealth platforms (Amwell, Teladoc), and wellness service providers. The company's integrated service model differentiates it from point-solution providers, though it faces competition from established healthcare networks and well-capitalized digital health platforms.
Industry Context
Novo Integrated Sciences, Inc. operates in Integrated Primary Care & Rehabilitative Healthcare Services.
Key facts
Founded: N/A · Headquarters: Bellevue, WA · Employees: N/A · Revenue: $13.29M (FY2024) · Market cap: N/A